| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:50 UTC |
|---|
| HMDB ID | HMDB0015038 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Methdilazine |
|---|
| Description | Methdilazine is only found in individuals that have used or taken this drug. It is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. |
|---|
| Structure | CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1 InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 10-[(1-Methyl-3-pyrrolidinyl)methyl]phenothiazine | ChEBI | | Dilosyn | ChEBI | | Metdilazina | ChEBI | | Methdilazinum | ChEBI | | MJ 5022 | ChEBI | | Tacaryl | ChEBI | | Tacazyl | ChEBI | | MD | HMDB | | Methdilazine monohydrochloride | HMDB | | Methodilazine | HMDB | | Methdilazine hydrochloride | HMDB |
|
|---|
| Chemical Formula | C18H20N2S |
|---|
| Average Molecular Weight | 296.43 |
|---|
| Monoisotopic Molecular Weight | 296.13471934 |
|---|
| IUPAC Name | 10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine |
|---|
| Traditional Name | methdilazine |
|---|
| CAS Registry Number | 1982-37-2 |
|---|
| SMILES | CN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1 |
|---|
| InChI Identifier | InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3 |
|---|
| InChI Key | HTMIBDQKFHUPSX-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzothiazines |
|---|
| Sub Class | Phenothiazines |
|---|
| Direct Parent | Phenothiazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenothiazine
- Alkyldiarylamine
- Diarylthioether
- Aryl thioether
- Tertiary aliphatic/aromatic amine
- Para-thiazine
- Benzenoid
- N-alkylpyrrolidine
- Pyrrolidine
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Thioether
- Hydrocarbon derivative
- Organic nitrogen compound
- Organonitrogen compound
- Organopnictogen compound
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 87 - 88 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.015 g/L | Not Available | | LogP | 4.3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.24 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.7239 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.95 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 58.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1019.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 250.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 158.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 183.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 106.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 346.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 405.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 693.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 864.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 276.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 890.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 222.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 332.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 399.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 389.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 24.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Methdilazine EI-B (Non-derivatized) | splash10-0002-9310000000-08a0f77b83bac7e129ee | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Methdilazine EI-B (Non-derivatized) | splash10-0002-9310000000-08a0f77b83bac7e129ee | 2018-05-18 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Methdilazine GC-MS (Non-derivatized) - 70eV, Positive | splash10-03e9-3190000000-f46571c32392cef17825 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Methdilazine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | MS | Mass Spectrum (Electron Ionization) | splash10-0002-9630000000-8f3e969116ed3e70d7e5 | 2014-09-20 | Not Available | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 10V, Positive-QTOF | splash10-0002-4090000000-160b71afca5a22413d1b | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 20V, Positive-QTOF | splash10-0002-9030000000-8d0d280a4305d9ee98b8 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 40V, Positive-QTOF | splash10-0pwa-9000000000-9bf2c2541da751eb73d1 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 10V, Negative-QTOF | splash10-0002-0090000000-1ab8cb488f1b6fbcfa89 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 20V, Negative-QTOF | splash10-000b-0960000000-51823d86df854fd0b7c9 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 40V, Negative-QTOF | splash10-0002-2910000000-35bf29f0bae2eb02a654 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 10V, Positive-QTOF | splash10-0002-0090000000-9779fa04045a2c96d57f | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 20V, Positive-QTOF | splash10-0002-1090000000-789730aa3b37623adfc1 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 40V, Positive-QTOF | splash10-0002-9230000000-cd9ffb7dec63f7fe8d12 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 10V, Negative-QTOF | splash10-0002-0090000000-908c3cef276d5324ab63 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 20V, Negative-QTOF | splash10-0002-0190000000-840a23c528d53f2591f2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Methdilazine 40V, Negative-QTOF | splash10-0002-0930000000-e8e7355d83e44f37c46e | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | |
|---|
| Biospecimen Locations | |
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00902 | | details | | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00902 | | details |
|
|---|
| Abnormal Concentrations |
|---|
| Not Available |
|---|
| Predicted Concentrations |
|---|
| |
| Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | None |
|---|
| Associated OMIM IDs | None |
|---|
| External Links |
|---|
| DrugBank ID | DB00902 |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | Not Available |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 14009 |
|---|
| KEGG Compound ID | C07175 |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Methdilazine |
|---|
| METLIN ID | Not Available |
|---|
| PubChem Compound | 14677 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 774910 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | Not Available |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Not Available |
|---|
| Material Safety Data Sheet (MSDS) | Not Available |
|---|
| General References | - Chattopadhyay D, Mukherjee T, Pal P, Saha B, Bhadra R: Altered membrane permeability as the basis of bactericidal action of methdilazine. J Antimicrob Chemother. 1998 Jul;42(1):83-6. [PubMed:9700532 ]
- Chattopadhyay D, Dastidar SG, Chakrabarty AN: Antimicrobial properties of methdilazine and its synergism with antibiotics and some chemotherapeutic agents. Arzneimittelforschung. 1988 Jul;38(7):869-72. [PubMed:2905130 ]
- Rani Basu L, Mazumdar K, Dutta NK, Karak P, Dastidar SG: Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. Microbiol Res. 2005;160(1):95-100. [PubMed:15782943 ]
|
|---|